Anti-β2-glycoprotein I and anti-prothrombin antibodies in patients with the 'antiphospholipid' syndrome: Immunological specificity and clotting profiles

Lupus

Volumn 7, Issue 5, 1998, Pages 323-332

  Kandiah, D A ^a   Krilis, S A ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

Author keywords

2 glycoprotein; 'Antiphospholipid' syndrome; Autoantibodies; Prothrombin

Indexed keywords

AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; LUPUS ANTICOAGULANT; PHOSPHOLIPID; PLASMA PROTEIN; POLYCLONAL ANTIBODY; PROTHROMBIN; GLYCOPROTEIN;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CROSS REACTION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; BLOOD; BLOOD CLOTTING TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; MIDDLE AGED;

ADULT; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; BLOOD COAGULATION TESTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; HUMANS; LUPUS COAGULATION INHIBITOR; MALE; MIDDLE AGED; PROTHROMBIN;

EID: 0031595775     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120398678920253     Document Type: Article

References (38)

1. McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49: 193-280.
2. Kandiah DA, Krilis SA. Immunology and methods of detection of antiphospholipid antibodies In. Asherson RA, Cervera R, Piette J-C, Shoenfeld Y (eds). The Antiphospholipid Syndrome. CRC Press: Boca Raton, 1996, pp 29-48.
3. Zarrabi MH et al. Immunologic and coagulation disorders in chlorpromazine-treated patients. Ann Intern Med 1979; 91: 194-199.
4. Schoen RT, Trentham DE. Drug-induced lupus: an adjuvant disease? Am J Med 1981; 71: 5-8
5. Cohen AJ, Philips TM, Kessler CM. Circulating coagulation inhibitors in the acquired immunodeficiency syndrome Ann Intern Med 1986; 104: 175-180.
6. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H) Proc Natl Acad Sci USA 1990; 87: 4120-4124.
7. Galli M et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-1547
8. Shapiro SS, Thiagarajan P. Lupus anticoagulants. Progress in Haemostasis and Thrombosis 1982; 6: 263-285
9. Loeliger A. Prothrombin as cofactor in the circulating anticoagulant in systemic lupus erythematosus? Thromb Diath Haemorrh 1959; 3: 237.
10. Edson JR, Vogt JM, Hasegawa DK. Abnormal prothrombin crossed immunoelectrophoresis in patients with lupus inhibitors Blood 1984; 64: 807-816.
11. Fleck RA, Rapaport SI, Rao LV. Anti-prothrombin antibodies and the lupus anticoagulant. Blood 1988; 72: 512-519.
12. Permpikul P, Rao LVM, Rapaport SI. Functional and binding studies of the roles of prothrombin and β2-glycoprotein I in the expression of lupus anticoagulant activity. Blood 1994; 83: 2878-2892.
13. Severs EM et al. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemostasis 1991; 66: 629-632.
14. Galli M, Finazzi G, Bevers EM, Barbui T Kaolin Clotting Time and dilute Russell's Viper Venom Time distinguish between prothrombin-dependent and β2-glycoprotein I-dependent antiphospholipid antibodies. Blood 1995; 86: 617-623.
15. Galli M et al. Anticoagulant activity of β2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemostasis 1992; 68: 297-300.
16. Arvieux J et al. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants Thromb Haemostasis 1995; 74: 1120-1125.
17. Sletnes KE, Gravem K, Wisloff F Preparation of plasma for the detection of lupus anticoagulants and antiphospholipid antibodies. Thromb Research 1992; 66: 43-53
18. Monestier M et al Monoclonal antibodies from NZW x BXSB/F1 mice to β2-glycoprotein I and cardiolipin. Species specificity and charge-dependent binding. J Immunol 1996; 156: 2631-2641
19. Ichikawa K. et al. β2-glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome Arthritis Rheum 1994; 37: 1453-1461
20. Wang MX et al. Epitope specificity of monoclonal anti-β2-glycoprotein I antibodies derived from patients with the Antiphospholipid syndrome J Immunol 1995; 155: 1629-1636.
21. Friguet B, Chaffotte AF, Djavadi-Ohaniance L, Goldberg ME. Measurements of the true affinity constant of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods 1985; 77: 305-319.
22. Kouts S, Wang MX, Adelstein S, Krilis S. Immunization of a rabbit with β2-glycoprotein I induces charge-dependent cross-reactive antibodies that bind anionic phospholipids and have similar reactivity as autoimmune anti-phospholipid antibodies. J Immunol 1995; 155: 958-966
23. Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell's Viper Venom Time for the diagnosis of lupus anticoagulant. Blood 1986; 68: 869-874.
24. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: An update. Thromb Haemostasis 1995; 74: 1185-1190.
25. Kandiah DA, Krilis SA. Immunology of antiphospholipid antibodies and their interaction with plasma proteins. Lupus 1996; 5: 153-155.
26. Kandiah DA, Krilis SA. The clotting assays dilute Russell's; Viper Venom Time (dRVVT) and dilute Kaolin Clotting Time (dKCT) detect different populations of antibodies in plasmas of individual patients with Lupus Anticoagulant activity. Arthritis Rheum 1997; 40 (suppl): 298 (abstract 1604).
27. Horbach DA et al. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Thromb Haemostasis 1996; 76: 916-924.
28. Tincani A et al. The anti-β2-glycoprotein I activity in human Antiphospholipid Syndrome sera is due to monoreactive low-affinity autoantibodies predicted to epitopes located on native β2-glycoprotein I and preserved during species' evolution J Immunol 1996; 157: 5732-5738
29. Willems GM et al. Role of divalency in the high-affinity binding of anticardiolipin antibody-β2-glycoprotein I complexes to lipid membranes. Biochemistry 1996; 35: 13833-13842.
30. Pengo V, Thiagarajan P, Shapiro SS, Heine MJ. Immunological specificity and mechanism of action of IgG lupus anticoagulants. Blood 1987; 70: 69-76.
31. Thiagarajan P, Shapiro SS, De Marco L. A monoclonal IgM/ coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J Clin Invest 1980; 66: 397-405.
32. Harris EN et al. Affinity-purified anti-cardiolipin and anti-DNA antibodies. J Clin Lab Immunol 1985; 17: 155-162.
33. Oosting JD et al. Lupus anticoagulant activity is frequently dependent on the presence of β2-glycoprotein I. Thromb Haemostasis 1992; 67: 499-502.
34. Roubey RAS, Pratt CW, Buyon JP, Winfield JB. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon β2-glycoprotein I. J Clin Invest 1992; 90: 1100-1104.
35. Wu JR, Lentz BR. Phospholipid-specific conformational changes in human prothrombin upon binding to procoagulant acidic lipid membranes. Thromb Haemostasis 1994; 71: 596-604.
36. Borowski M, Furie BC, Bauminger S, Furie B. Prothrombin requires two sequential metal-dependent conformational transitions to bind phospholipids. J Biol Chem 1986; 261: 14969-14975.
37. Galli M et al. Different anticoagulant and immunological properties of anti-prothombin antibodies in patients with antiphospholipid antibodies. Thromb Haemostasis 1997; 77: 486-491.
38. Forastiero RR et al. Relationship of anti-β2-glycoprotein I and antiprothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thromb Haemostasis 1997; 78: 1008-1014.